Skip to main content

Advertisement

Table 4 Patients characteristics and symptomatic DVT

From: IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics

  DVD(-) DVT(+)  
Characteristics n = 318 n = 56 p
Age 68.2 ± 11.6 ( 25-90 ) 74.5 ± 7.8 (45-86) <0.00001
   Age75 yr 106   32   0.001
   Age < 75 yr 212   24   
Gender(male/female) 60/258   5/51   0.070
BMI(Kg/m2) 24.7 ± 4.2 (13.7-41.4) 25.8 ± 3.8 (20.1-35.1) 0.088
   BMI30 37   10   0.195
   BMI < 30 281   46   
Risk factors 176(55.3%)   38(67.9%)   0.081
TKA/THA 125/193   35/21   0.001
OA/RA 273/46   48/7   0.697
Seroconvertion of IgG-class Anti-PF4/heparin Ab 54(17.0%)   20(35.7%)   0.001
Treatment      
   UFH 89 (27.7%) 16 (28.6%) 0.890
   LMWH 81 (25.5%) 14 (25.0%) 0.940
   Fondaparinux 73 (23.0%) 8 (14.3%) 0.146
   Others 37 (11.6%) 13 (23.2%)  
Aspirin 31 (9.7%) 12 (21.4%)  
Warfarin 5 (1.6%) 0   
Cilostazol 26 (8.2%) 11 (19.6%)  
   No medication 39 (12.3%) 5 (8.9%) 0.475
  1. Abbreviations: DVT; deep vein thrombosis; BMI; body mass index, TKA; total knee arthroplasty, THA; total hip arthroplasty, OA; osteoarthritis, RA; rheumatoid arthritis, UFH; unfractionated heparin, LMWH; low-molecular weight heparin